Institutional Review Board, Hospital for Special Surgery
June 01, 2011
The safety of study participants is our top priority. The trial is approved and periodically reviewed by an Institutional Review Board (IRB), which includes doctors, administrators, ethicists, and members of the general public. The safety of clinical trials is reviewed by the U.S. Food and Drug Administration.
Before enrolling in a clinical trial, the investigator will explain the purpose of the trial, its expected benefits, any possible risks or side effects, and what your role will be. This is the time to ask questions! If you want to join the trial, you must sign the informed consent documents. You can leave a clinical trial at any time without penalty.
For further information, see Understanding Clinical Trials.
Krystle A. Hearns
Tracy E. Klein
R. Glenn Gaston, MD
Susan M. Odum, MD
Thomas A. Wiedrich, MD
The goal in creating a national registry for elite athlete hand injury, treatment, and outcomes is both to define the epidemiology of hand injuries within this population and to collaboratively evaluate surgical treatment and return-to-play guidelines for elite athletes. The long-term objectives are to refine treatment protocols based upon outcomes evidence, and to prevent re-injury and long-term sequelae resulting from sports-related hand injury. Patients will be enrolled starting in August 2011.